OCS Stock Overview
A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Oculis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2,120.00 |
| 52 Week High | US$2,500.00 |
| 52 Week Low | US$1,500.00 |
| Beta | 0.0083 |
| 11 Month Change | -3.64% |
| 3 Month Change | 26.19% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 25.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCS | IS Pharmaceuticals | IS Market | |
|---|---|---|---|
| 7D | 1.9% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how OCS performed against the IS Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how OCS performed against the IS Market.
Price Volatility
| OCS volatility | |
|---|---|
| OCS Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in IS Market | 0% |
| 10% least volatile stocks in IS Market | 0% |
Stable Share Price: OCS's share price has been volatile over the past 3 months compared to the IS market.
Volatility Over Time: OCS's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of IS stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 36 | Riad Sherif | oculis.com |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Oculis Holding AG Fundamentals Summary
| OCS fundamental statistics | |
|---|---|
| Market cap | ISK 85.67b |
| Earnings (TTM) | -ISK 10.83b |
| Revenue (TTM) | ISK 135.04m |
634.4x
P/S Ratio-7.9x
P/E RatioIs OCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCS income statement (TTM) | |
|---|---|
| Revenue | CHF 868.00k |
| Cost of Revenue | CHF 48.35m |
| Gross Profit | -CHF 47.48m |
| Other Expenses | CHF 22.14m |
| Earnings | -CHF 69.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | -5,470.16% |
| Net Profit Margin | -8,020.85% |
| Debt/Equity Ratio | 0% |
How did OCS perform over the long term?
See historical performance and comparison